Zacks Investment Research on MSN11h
LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug ...
Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.
Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...
As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks ...
Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...
Lexicon is eligible to receive upfront and near-term milestone payments of up to $75 million. In total, Lexicon will be eligible to receive $1 billion in upfront and potential development, regulatory ...
Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...
Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential ...
Lexicon Pharmaceuticals (LXRX) announced that it has entered into an exclusive license agreement with Novo Nordisk (NVO) for LX9851, a ...
Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...
THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback